This report is based on public company disclosures, filings and announcements reviewed by GSN; figures are as stated by the company and have not been independently verified.

Zenas BioPharma Inc (Nasdaq: ZBIO) announced on September 22, 2026, that it will present new clinical data regarding its drug candidate obexelimab at two upcoming scientific meetings. The company stated that the data originates from the Phase 3 INDIGO trial, which evaluates obexelimab for the treatment of immunoglobulin G4-related disease. The presentations are scheduled for the 6th International Symposium on IgG4-Related Disease in Cambridge, Massachusetts, and the American College of Rheumatology Convergence 2026 in Orlando, Florida.

Zenas BioPharma is a clinical-stage global biopharmaceutical company advancing therapies for patients living with autoimmune and inflammatory diseases. The company develops obexelimab, a bifunctional monoclonal antibody designed to bind both CD19 and FcγRIIb. This mechanism aims to inhibit the activity of cells implicated in autoimmune diseases without depleting them. The drug is administered via a self-administered subcutaneous injection regimen.

Key terms

Phase 3 clinical trial. This is the late-stage testing step for a new drug or medical treatment. It involves giving the product to large groups of patients to confirm effectiveness, monitor side effects, and compare it to standard care. Successful Phase 3 results are often the final scientific hurdle before regulators decide on approval and market launch.

Open-label extension. This is a continuation of a clinical trial where all participants and researchers know which treatment is being given. It often occurs after an initial blinded phase. It allows for further study of a drug’s long-term safety and effectiveness.

Glucocorticoid-associated toxicity. Glucocorticoids are a class of steroid hormones used to treat inflammation. Long-term use can cause various side effects known as toxicity. Assessing this toxicity is important for determining the safety profile of a new treatment compared to existing standards.

Why it matters

Clinical trial data presentations at major scientific meetings allow researchers and clinicians to review detailed findings before regulatory submissions are finalized. For a company in the clinical stage, these presentations provide an opportunity to share long-term efficacy and safety data with the medical community. This process helps build scientific understanding of the disease and the potential role of the therapy. It does not constitute regulatory approval or a guarantee of future commercial success. Investors and analysts use this information to assess the robustness of the clinical program and the potential market for the drug.

What to watch

The documents state that longer-term flare protection and safety data from the INDIGO open-label extension will be presented on October 10 at the 6th International Symposium on IgG4-Related Disease. Additional presentations covering glucocorticoid-associated toxicity and vaccine responses will occur at the American College of Rheumatology Convergence 2026 in November 2026. The company also noted that topline results for the Phase 2 SunStone trial in Systemic Lupus Erythematosus are expected in the fourth quarter of 2026.

Sources